Kiniksa Pharmaceuticals International, plc (KNSA) Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Kiniksa Pharmaceuticals International, plc NASDAQ:KNSA Healthcare · Medical - Pharmaceuticals
Mkt Cap $7.25B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up roughly 58% year-over-year from $180.9 million, with net income of $47.3 million versus $18.4 million a year ago.
The company raised 2026 ARCALYST revenue guidance to $1.045-$1.050 billion from the prior $980-$995 million range, putting the drug on track for blockbuster status this year.
The balance sheet holds $568.8 million in cash and short-term investments with no debt, and management expects the operating plan to remain cash flow positive annually.
Pipeline execution continues with the pivotal Phase 3 PASTORALE trial of KPL-387 enrolling (data expected 2H 2027) and a Phase 1 first-in-human trial of KPL-1161 on track to start by year-end 2026.
• 5d ago AI analysis › Press Release
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
Kiniksa Pharmaceuticals announced it will report third quarter 2026 financial results on Tuesday, October 27, 2026, via a conference call and live webcast at 8:30 a.m. Eastern Time.
The webcast will be available through the Investors & Media section of the company's website, with a replay posted within approximately 48 hours.
The notice contains no financial results, guidance, or operational updates.
• 10d ago AI analysis › Press Release
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa Pharmaceuticals International, plc will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
A live webcast will be accessible through the Investors section of Kiniksa's website, with a replay available within approximately 48 hours after the event.
Kiniksa is a biopharmaceutical company focused on developing and commercializing novel therapies for debilitating diseases with unmet need, with an emphasis on cardiovascular indications.
• 1mo ago AI analysis › Press Release
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Kiniksa Pharmaceuticals management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026.
The live presentation is scheduled for 9:00 a.m. Eastern Time, with a webcast available via the Investors section of the company's website.
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, and commercializing novel therapies for cardiovascular indications.
• 2mo ago AI analysis › Press Release ● Major
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q2 revenue of $243.6 million, up 55% year-over-year, driven by growth in ARCALYST prescriptions for recurrent pericarditis.
Management raised full-year 2026 ARCALYST guidance to $980 million-$995 million, up from the previous $930 million-$945 million range.
The company reported positive Phase 2 data for KPL-387, showing rapid pain and inflammation reduction, and has initiated enrollment in the pivotal Phase 3 PASTORALE trial.
• 3mo ago AI analysis › Press Release
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
Kiniksa Pharmaceuticals announced it will report second quarter 2026 financial results on July 28, 2026, via a conference call at 8:30 a.m. Eastern Time.
Management will discuss recent portfolio execution alongside the financial results during the live webcast, accessible through the company's website.
A replay of the call will be made available approximately 48 hours after the event concludes.
• 3mo ago AI analysis › Press Release
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals will present at two major healthcare investor conferences in June.
Management is scheduled for a fireside chat at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 9.
Live webcasts and replays will be available on the company's investor relations website.
• 5mo ago AI analysis › Press Release ● Major
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q1 2026 revenue of $214.3 million, a 56% increase year-over-year, driven by strong adoption of ARCALYST for recurrent pericarditis and expanding prescriber base.
Following the robust performance, the company raised its full-year 2026 ARCALYST net sales guidance to between $930 million and $945 million, up from the prior range of $900 million to $920 million.
The company ended the quarter with $468.1 million in cash and remains on track to report Phase 2 data for KPL-387 in the second half of 2026 with a Phase 3 trial initiating by year-end.
• 6mo ago AI analysis › 
